Microrna-203 Represses Selection and Expansion of Oncogenic Hras Transformed Tumor Initiating Cells

Total Page:16

File Type:pdf, Size:1020Kb

Microrna-203 Represses Selection and Expansion of Oncogenic Hras Transformed Tumor Initiating Cells 1 MicroRNA-203 represses selection and expansion of oncogenic 2 Hras transformed tumor initiating cells 3 4 Kent Riemondy1, Xiao-jing Wang2, Enrique C. Torchia3, Dennis R. Roop3 and Rui Yi1,4 5 6 1Department of Molecular, Cellular, and Developmental Biology, University of Colorado, 7 Boulder, Boulder, CO 80309 8 2Department of Pathology, University of Colorado Denver Anschutz Medical Campus, Aurora, 9 CO 80045 10 3Department of Dermatology and Charles C. Gates Center for Regenerative Medicine and Stem 11 Cell Biology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045 12 13 4Correspondence: 14 Rui Yi 15 Department of Molecular, Cellular, and Developmental Biology 16 University of Colorado, Boulder 17 Boulder, CO USA 80303 18 Tel: 303-735-4886 19 Email: [email protected] 20 21 Competing Interests Statement 22 The authors declare no competing interests. 1 23 Abstract 24 In many mouse models of skin cancer, only a few tumors typically form even though many cells 25 competent for tumorigenesis receive the same oncogenic stimuli. These observations suggest an 26 active selection process for tumor-initiating cells. Here we use quantitative mRNA- and miR-Seq 27 to determine the impact of HrasG12V on the transcriptome of keratinocytes. We discover that 28 microRNA-203 is downregulated by HrasG12V. Using a knockout mouse model, we demonstrate 29 that loss of microRNA-203 promotes selection and expansion of tumor-initiating cells. 30 Conversely, restoration of microRNA-203 using an inducible model potently inhibits 31 proliferation of these cells. We comprehensively identify microRNA-203 targets required for 32 Hras-initiated tumorigenesis. These targets include critical regulators of the Ras pathway and 33 essential genes required for cell division. This study establishes a role for the loss of microRNA- 34 203 in promoting selection and expansion of Hras mutated cells and identifies a mechanism 35 through which microRNA-203 antagonizes Hras-mediated tumorigenesis. 36 37 38 39 40 41 42 43 44 45 46 2 47 Introduction 48 Recent efforts in comprehensively sequencing human cancer genomes have confirmed 49 ~140 protein-coding genes that, when mutated, can drive tumorigenesis [1]. When genome 50 sequencing data were utilized to construct the history of cancer cells in breast cancer, it was 51 revealed that a considerable amount of “molecular time” exists between the common ancestors 52 that harbor the great majority of driver mutations and the phenotypically identified cancer cells 53 that compose the bulk of the tumor [2]. In support of these observations, lineage tracing 54 experiments conducted in genetically engineered mouse models revealed only a few clones give 55 rise to tumors whereas a vast majority of mutated cells are unable to sustain tumorigenesis [3,4]. 56 These results suggest that even after the acquisition of key driver mutations in the nascent cancer 57 cells, these cells must still undergo continuous evolution and likely clonal selection before 58 developing into clinically apparent tumors. To begin to understand the molecular basis 59 underlying such selection, we examined papilloma formation driven by oncogenic Hras in the 60 skin, a well characterized model where Hras has been shown to initiate the formation of tumors 61 that clonally evolve [3,5,6]. Oncogenic Ras mutations are some of the most frequently detected 62 driver mutations in human cancer. Among the three Ras genes (H-, K- and N-ras), Hras is 63 commonly mutated in tumors originated from stratified epithelial tissues including squamous cell 64 carcinoma in the skin, head and neck cancer as well as bladder cancer [7–9]. Experimental and 65 genomic sequencing studies have revealed that the vast majority of Ras mutations are missense, 66 point mutations at amino acid residues glycine 12 (G12), glycine 13 (G13) or glutamine 61 67 (Q61) [8]. Structural and biochemical studies have further confirmed that all of these mutations 68 generally interfere with the GTP binding pocket and compromise the GTPase activity of Ras 69 proteins. In turn, these mutations lead to uncontrolled activation of downstream effectors 3 70 including Raf/MEK/ERK and PI(3)K pathways, resulting in sustained cell survival and 71 proliferation observed in human cancers. Because of the prominent role of Ras mutations in 72 human cancer, extensive efforts have been devoted to uncover and subsequently target 73 downstream pathways that are regulated by Ras mutations. However, the immediate impact of 74 Ras mutations on the transcriptome, in particular with regards to microRNAs (miRNAs) remains 75 unclear. 76 miRNAs are a class of small, noncoding RNA species that are involved in virtually all 77 biological processes examined in mammals including mouse and human. These regulatory RNA 78 molecules function by repressing the protein producing ability of mRNA targets through 79 destabilization of mRNAs and inhibition of translation [10]. miRNAs typically target a large 80 number of mRNAs in a dosage- and cell context-dependent manner [11]. As prominent proto- 81 oncogenes, Ras mutations have long been recognized to interact with the miRNA pathway. 82 Indeed, Hras, Kras and Nras all harbor multiple binding sites for the let-7 miRNA, a founding 83 member of miRNAs, in their 3’UTRs [12]. Additionally, impaired miRNA biogenesis in the 84 form of Dicer1 disruption has been shown to be a tumor suppressing mechanism for the 85 development of Kras induced lung cancer in a mouse model [13]. A number of individual 86 miRNAs were also found to function as modifiers for Ras induced tumorigenesis that include 87 miR-21, -29 and miR-17~92 as tumor promoting miRNAs and miR-34, -15/16, and miR-143/145 88 as tumor suppressing miRNAs [14–16]. Collectively, these seminal studies demonstrate 89 unequivocally that the miRNA pathway and individual miRNAs play important roles in Ras- 90 induced tumorigenesis. However, it is unclear how Ras mutations, usually the tumor-initiating 91 drivers, directly alter the landscape of miRNA expression during tumorigenesis. Importantly, it is 92 also unknown whether the changes in miRNA expression play a role in the selection of 4 93 oncogenic Ras transformed cells during tumor initiation. Finally, the lack of a comprehensive 94 survey of high-confidence miRNA targets that may play a role downstream of Ras mutations 95 hinders our mechanistic understanding and limits the potential to develop miRNA based 96 therapeutics. 97 In this study, we utilized our recently improved quantitative miR-Seq techniques to 98 examine the impact of an oncogenic Hras mutation (HrasG12V) on both mRNA and miRNA 99 expression. We discovered that miR-203, the most highly expressed miRNA in the skin [17,18], 100 is downregulated by HrasG12V. Using both knockout (KO) and inducible models, we provide 101 evidence for an important role of miR-203 in restricting expansion of oncogenic Hras 102 transformed cells in vitro and in vivo. We comprehensively surveyed skin-specific targets of 103 miR-203 and identified a number of novel targets that have important implications for Hras- 104 mediated tumorigenesis. Our results suggest that miR-203 plays a tumor-suppressing role in 105 inhibiting selection and expansion of tumor-initiating cells early in tumor development. 106 107 Results: 108 HrasG12V profoundly deregulates the mRNA and miRNA transcriptome in the skin 109 Oncogenic mutation of the Hras gene is one of the initiating drivers in the development 110 of benign papillomas and malignant squamous cell carcinomas in murine skin chemical 111 carcinogenesis. However, the molecular consequences defining the cellular changes that 112 accompany expansion of oncogenic Hras-transformed keratinocytes to initiate papillomas 113 remain elusive. We first investigated the consequences of HrasG12V activation on the mRNA 114 transcriptome using a modified form of PolyA+ RNA-Seq, known as 3P-Seq, or 3seq (Figure 115 1A-C). Compared to traditional RNA-Seq, 3Seq allows both quantification of mRNA transcripts 5 116 and detection of changes in alternative 3’ UTR formation [19]. To examine the immediate 117 impact of HrasG12V on primary skin cells, we used primary keratinocytes isolated from newborn 118 skin and performed 3Seq after HrasG12V transduction. We did not observe widespread shortening 119 or alternative formation of 3’UTRs, which are often ascribed to oncogenic transformation when 120 comparing tumor cell lines to normal cells (data not shown). This is similar to our previous 121 observation that alternative 3’UTR usage is infrequent within the skin lineages [19]. Over 1,100 122 transcripts were differently expressed (two-fold change and FDR <0.05) in keratinocytes 123 expressing HrasG12V, compared to the control (Figure 1C and Figure 1-source data). Gene 124 ontology functional analysis revealed profound deregulation in three core processes by HrasG12V: 125 activation of cellular migration, upregulation of pro-angiogenic pathways, and suppression of the 126 terminal differentiation program (Figure 1D). All of these three processes are identified as 127 hallmarks of human cancer [20]. The observed widespread changes in the transcriptome also 128 endorse the driver role of HrasG12V in skin tumorigenesis. Importantly, transcripts upregulated by 129 HrasG12V in our primary keratinocytes strongly and significantly overlapped with the putative 130 cancer stem cell signatures obtained from murine squamous cell carcinoma (SCC) models [21]. 131 In addition, transcripts upregulated by HrasG12V significantly overlapped with transcripts know to 132 be targets of the c-Fos transcription factor in a genetic model of SCC [22]. Furthermore, known 133 core components of the Hras signaling pathway were also among the differentially detected 134 genes [23] (Figure 1E). These transcriptome data indicate that we have captured the initiating 135 changes induced by oncogenic Hras in the keratinocytes. 136 To define the impact of the oncogenic Hras on the landscape of miRNA, we applied our 137 recently developed, quantitative miRNA-Seq [24] to HrasG12V transformed keratinocytes. Overall, 138 we detected 15 differentially expressed miRNAs upon HrasG12V expression (FDR <0.05, two- 6 139 fold change) (Figure 1F-H).
Recommended publications
  • Nanoliposomal Delivery of Microrna-203 Suppresses Migration of Triple-Negative Breast Cancer Through Distinct Target Suppression
    non-coding RNA Article Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression Shuxuan Song 1, Kelsey S. Johnson 1, Henry Lujan 2, Sahar H. Pradhan 2 , Christie M. Sayes 2 and Joseph H. Taube 1,* 1 Department of Biology, Baylor University, Waco, TX 76706, USA; [email protected] (S.S.); [email protected] (K.S.J.) 2 Department of Environmental Science, Baylor University, Waco, TX 76706, USA; [email protected] (H.L.); [email protected] (S.H.P.); [email protected] (C.M.S.) * Correspondence: [email protected] Abstract: Triple-negative breast cancers affect thousands of women in the United States and dis- proportionately drive mortality from breast cancer. MicroRNAs are small, non-coding RNAs that negatively regulate gene expression post-transcriptionally by inhibiting target mRNA translation or by promoting mRNA degradation. We have identified that miRNA-203, silenced by epithelial– mesenchymal transition (EMT), is a tumor suppressor and can promote differentiation of breast cancer stem cells. In this study, we tested the ability of liposomal delivery of miR-203 to reverse aspects of breast cancer pathogenesis using breast cancer and EMT cell lines. We show that transla- tionally relevant methods for increasing miR-203 abundance within a target tissue affects cellular Citation: Song, S.; Johnson, K.S.; properties associated with cancer progression. While stable miR-203 expression suppresses LASP1 Lujan, H.; Pradhan, S.H.; Sayes, C.M.; and survivin, nanoliposomal delivery suppresses BMI1, indicating that suppression of distinct mRNA Taube, J.H. Nanoliposomal Delivery target profiles can lead to loss of cancer cell migration.
    [Show full text]
  • Immune Function of Mir-214 and Its Application Prospects As Molecular Marker
    Immune function of miR-214 and its application prospects as molecular marker Qiuyuan Wang, Yang Liu, Yiru Wu, Jie Wen and Chaolai Man College of Life Science and Technology, Harbin Normal University, Harbin, China ABSTRACT MicroRNAs are a class of evolutionary conserved non-coding small RNAs that play key regulatory roles at the post-transcriptional level. In recent years, studies have shown that miR-214 plays an important role in regulating several biological processes such as cell proliferation and differentiation, tumorigenesis, inflammation and immunity, and it has become a hotspot in the miRNA field. In this review, the regulatory functions of miR-214 in the proliferation, differentiation and functional activities of immune- related cells, such as dendritic cells, T cells and NK cells, were briefly reviewed. Also, the mechanisms of miR-214 involved in tumor immunity, inflammatory regulation and antivirus were discussed. Finally, the value and application prospects of miR-214 as a molecular marker in inflammation and tumor related diseases were analyzed briefly. We hope it can provide reference for further study on the mechanism and application of miR-214. Subjects Biochemistry, Molecular Biology, Immunology Keywords miR-214, Immune cell, Tumor immunity, Inflammation, Virus, Molecular marker INTRODUCTION MicroRNAs (miRNAs) are a kind of high conserved non-coding small RNAs in evolution that bind to the 30-untranslated region (30-UTR) of target gene mRNA and regulate gene Submitted 18 September 2020 expression at post-transcriptional level. In immune responses, miRNAs act as signal- Accepted 20 January 2021 Published 16 February 2021 regulating molecules after immune-related receptors activation, and affect the expression Corresponding author of immune-related genes, thus extensively participating in various aspects of immune Chaolai Man, [email protected] response (Bosisio et al., 2019; Mehta & Baltimore, 2016).
    [Show full text]
  • ANT2 Shrna Downregulates Mir-19A and Mir-96 Through the PI3K/Akt Pathway and Suppresses Tumor Growth in Hepatocellular Carcinoma Cells
    OPEN Experimental & Molecular Medicine (2016) 48, e222; doi:10.1038/emm.2015.126 & 2016 KSBMB. All rights reserved 2092-6413/16 www.nature.com/emm ORIGINAL ARTICLE ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells Seung Hyun Baik1,3, Jongkuen Lee1,3, Yeong-Shin Lee1,3, Ji-Young Jang1 and Chul-Woo Kim1,2 MicroRNAs (miRNAs) are negative regulators of gene expression, and miRNA deregulation is found in various tumors. We previously reported that suppression of adenine nucleotide translocase 2 (ANT2) by short hairpin RNA (shRNA) inhibits hepatocellular carcinoma (HCC) development by rescuing miR-636 expression. However, the tumor-suppressive mechanisms of ANT2 shRNA are still poorly understood in HCC. Here, we hypothesized that miRNAs that are specifically downregulated by ANT2 shRNA might function as oncomiRs, and we investigated the roles of ANT2 shRNA-regulated miRNAs in the pathogenesis of HCC. Our data show that miR-19a and miR-96, whose expression is regulated by ANT2 suppression, were markedly upregulated in HCC cell lines and clinical samples. Ectopic expression of miR-19a and miR-96 dramatically induced the proliferation and colony formation of hepatoma cells in vitro, whereas inhibition of miR-19a and miR-96 reduced these effects. To investigate the in vivo function, we implanted miR-96-overexpressing HepG2 cells in a xenograft model and demonstrated that the increase in miR-96 promoted tumor growth. We also found that miR-19a and miR-96 inhibited expression of tissue inhibitor of metalloproteinase-2. Taken together, our results suggest that ANT2-regulated miR-19a and miR-96 play an important role in promoting the proliferation of human HCC cells, and the knockdown of ANT2 directly downregulates miR-19a and miR-96, ultimately resulting in the suppression of tumor growth.
    [Show full text]
  • Elevated Circulating Microrna-122 Is Associated with Obesity and Insulin Resistance in Young Adults
    R Wang, J Hong, Y Cao and miR-122, obesity and insulin 172:3 291–300 Clinical Study others resistance Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults Rui Wang1,*, Jie Hong1,*, Yanan Cao1,*, Juan Shi1, Weiqiong Gu1, Guang Ning1,2, Yifei Zhang1 and Weiqing Wang1 1Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism, Shanghai Key Laboratory for Endocrine Tumors and E-Institutes of Shanghai Universities, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China and 2Laboratory for Endocrine and Metabolism, Institute of Health Sciences, Correspondence Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School should be addressed of Medicine, Shanghai 200025, China to W Wang *(R Wang, J Hong and Y Cao contributed equally to this work) Email [email protected] Abstract Objective: MicroRNAs (miRNAs) are involved in the regulation of adiposity, but functional studies have yielded inconclusive results. Examining the associations of circulating miRNAs levels with obesity and insulin sensitivity in humans may lead to improved insights. Design and methods: Serum samples collected from 112 obese and control subjects (50.0% men) were randomly divided and combined into four pools (28 samples in each obese or control pool). The genome-wide circulating miRNA profiles were detected via microarray. Elevated miR-122 was selected and validated in individual serum samples from 123 obese (46.7% men) and 107 control (50.0% men) young adults. Associations between circulating miR-122 levels and parameters related to adiposity, insulin resistance, lipid profiles and hepatic enzymes were further assessed.
    [Show full text]
  • Microrna Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms Behind Variable Drug Disposition and Strategy to Develop More Effective Therapy
    1521-009X/44/3/308–319$25.00 http://dx.doi.org/10.1124/dmd.115.067470 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:308–319, March 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Minireview MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy Ai-Ming Yu, Ye Tian, Mei-Juan Tu, Pui Yan Ho, and Joseph L. Jilek Department of Biochemistry & Molecular Medicine, University of California Davis School of Medicine, Sacramento, California Received September 30, 2015; accepted November 12, 2015 Downloaded from ABSTRACT Knowledge of drug absorption, distribution, metabolism, and excre- we review the advances in miRNA pharmacoepigenetics including tion (ADME) or pharmacokinetics properties is essential for drug the mechanistic actions of miRNAs in the modulation of Phase I and development and safe use of medicine. Varied or altered ADME may II drug-metabolizing enzymes, efflux and uptake transporters, and lead to a loss of efficacy or adverse drug effects. Understanding the xenobiotic receptors or transcription factors after briefly introducing causes of variations in drug disposition and response has proven the characteristics of miRNA-mediated posttranscriptional gene dmd.aspetjournals.org critical for the practice of personalized or precision medicine. The regulation. Consequently, miRNAs may have significant influence rise of noncoding microRNA (miRNA) pharmacoepigenetics and on drug disposition and response. Therefore, research on miRNA pharmacoepigenomics has come with accumulating evidence sup- pharmacoepigenetics shall not only improve mechanistic under- porting the role of miRNAs in the modulation of ADME gene standing of variations in pharmacotherapy but also provide novel expression and then drug disposition and response.
    [Show full text]
  • Microrna-155 Modulates Bile Duct Inflammation by Targeting the Suppressor of Cytokine Signaling 1 in Biliary Atresia
    nature publishing group Basic Science Investigation | Articles MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia Rui Zhao1, Rui Dong1, Yifan Yang1, Yuqing Wang1, Jin Ma2, Jiang Wang1, Hao Li1 and Shan Zheng1 BACKGROUND: Biliary atresia (BA) is an etiologically etiology and pathogenesis of BA remains largely unknown. A perplexing disease, manifested by neonatal cholestasis, leading hypothesis for the pathogenesis of BA is a virus repeated cholangitis, and progressive biliary fibrosis. MiR-155 infection-initiated bile duct injury (possibly prenatal), which has been implicated to modulate the immune response, is then followed by an exaggerated inflammatory or which contributes to biliary injury. However, its potential role autoimmune response targeting the bile duct epithelium. in the pathogenesis of BA has not been addressed so far. This ultimately results in progressive bile duct injury, METHODS: The microRNA changes from BA patients and obliteration, and secondary biliary cirrhosis (3,4). controls were identified via microarray. The immunomodula- Gene expression is primarily regulated at a post- tory function of miR-155 was investigated via cell transfection transcriptional level by microRNAs (miRNAs), which exert and reporter assay. The lentiviral vector pL-miR-155 inhibitor their function by targeting complementary mRNA molecules, was transfected into a mouse model to investigate its thus inhibiting their translation by binding to the 3′ role in BA. untranslated region (UTR) (5). Many miRNAs have been RESULTS: The expression of miR-155 in livers of BA patients reported to be differentially expressed in autoimmune diseases was significantly increased, and an inverse correlation and consequently may have a pivotal role in the regulation of between miR-155 and suppressor of cytokine signaling 1 both immune responses and autoimmunity.
    [Show full text]
  • METTL1 Promotes Let-7 Microrna Processing Via M7g Methylation
    Article METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation Graphical Abstract Authors Luca Pandolfini, Isaia Barbieri, Andrew J. Bannister, ..., Mara d’Onofrio, Shankar Balasubramanian, Tony Kouzarides Correspondence [email protected] In Brief Pandolfini, Barbieri, et al. show that a subgroup of tumor suppressor microRNAs, including let-7e, contain 7-methylguanosine (m7G). Methyltransferase METTL1 is required for m7G modification of miRNAs, their efficient processing, and the inhibition of lung cancer cell migration. Structurally, m7G in miRNA precursors antagonizes RNA secondary structures that would otherwise inhibit their maturation. Highlights Data Resource d Internal m7G is identified in miRNAs by two independent GSE112182 sequencing techniques GSE112180 GSE112181 d Methyltransferase METTL1 mediates m7G modification of GSE120454 specific miRNAs GSE120455 d METTL1 promotes miRNA maturation and suppresses lung cancer cell migration d m7G promotes processing by antagonizing G-quadruplex structures in miRNA precursors Pandolfini et al., 2019, Molecular Cell 74, 1278–1290 June 20, 2019 ª 2019 The Author(s). Published by Elsevier Inc. https://doi.org/10.1016/j.molcel.2019.03.040 Molecular Cell Article METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation Luca Pandolfini,1,9 Isaia Barbieri,1,2,9 Andrew J. Bannister,1 Alan Hendrick,3 Byron Andrews,3 Natalie Webster,3 Pierre Murat,4,7 Pia Mach,1 Rossella Brandi,5 Samuel C. Robson,1,8 Valentina Migliori,1 Andrej Alendar,1 Mara d’Onofrio,5,6 Shankar Balasubramanian,4
    [Show full text]
  • Chronic Exposure of Humans to High Level Natural Background Radiation Leads to Robust Expression of Protective Stress Response Proteins S
    www.nature.com/scientificreports OPEN Chronic exposure of humans to high level natural background radiation leads to robust expression of protective stress response proteins S. Nishad1,2, Pankaj Kumar Chauhan3, R. Sowdhamini3 & Anu Ghosh1,2* Understanding exposures to low doses of ionizing radiation are relevant since most environmental, diagnostic radiology and occupational exposures lie in this region. However, the molecular mechanisms that drive cellular responses at these doses, and the subsequent health outcomes, remain unclear. A local monazite-rich high level natural radiation area (HLNRA) in the state of Kerala on the south-west coast of Indian subcontinent show radiation doses extending from ≤ 1 to ≥ 45 mGy/y and thus, serve as a model resource to understand low dose mechanisms directly on healthy humans. We performed quantitative discovery proteomics based on multiplexed isobaric tags (iTRAQ) coupled with LC–MS/MS on human peripheral blood mononuclear cells from HLNRA individuals. Several proteins involved in diverse biological processes such as DNA repair, RNA processing, chromatin modifcations and cytoskeletal organization showed distinct expression in HLNRA individuals, suggestive of both recovery and adaptation to low dose radiation. In protein–protein interaction (PPI) networks, YWHAZ (14-3-3ζ) emerged as the top-most hub protein that may direct phosphorylation driven pro- survival cellular processes against radiation stress. PPI networks also identifed an integral role for the cytoskeletal protein ACTB, signaling protein PRKACA; and the molecular chaperone HSPA8. The data will allow better integration of radiation biology and epidemiology for risk assessment [Data are available via ProteomeXchange with identifer PXD022380]. Te basic principles of low linear energy transfer (LET) ionizing radiation (IR) induced efects on mammalian systems have been broadly explored and there exists comprehensive knowledge on the health efects of high doses of IR delivered at high dose rates.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Molecular Pathogenesis and Regulation of the Mir-29-3P-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma
    cancers Article Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma Yuto Hozaka 1 , Naohiko Seki 2,* , Takako Tanaka 1, Shunichi Asai 2, Shogo Moriya 3, Tetsuya Idichi 1, Masumi Wada 1, Kiyonori Tanoue 1, Yota Kawasaki 1, Yuko Mataki 1 , Hiroshi Kurahara 1 and Takao Ohtsuka 1 1 Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan; [email protected] (Y.H.); [email protected] (T.T.); [email protected] (T.I.); [email protected] (M.W.); [email protected] (K.T.); [email protected] (Y.K.); [email protected] (Y.M.); [email protected] (H.K.); [email protected] (T.O.) 2 Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; [email protected] 3 Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-43-226-2971 Simple Summary: Even today, there are no effective targeted therapies for intrahepatic cholan- giocarcinoma (ICC) patients. Clarifying the molecular pathogenesis of ICC will contribute to the Citation: Hozaka, Y.; Seki, N.; development of treatment strategies for this disease. In this study, we searched for the role of the Tanaka, T.; Asai, S.; Moriya, S.; Idichi, miR-29-3p-family and its association with oncogenic pathway. Interestingly, aberrant expression of T.; Wada, M.; Tanoue, K.; Kawasaki, ITGA6 and ITGB1 was directly regulated by the miR-29-3p-family which are involved in multiple Y.; Mataki, Y.; et al.
    [Show full text]
  • Exploring the Role of a PYHIN Protein and Involvement of Caspase-8 in the Regulation and Activation of Inflammasomes
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2017-09-12 Different Journeys, Same Destination: Exploring the Role of a PYHIN Protein and Involvement of Caspase-8 in the Regulation and Activation of Inflammasomes Sreya Ghosh University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Immunity Commons, Immunology of Infectious Disease Commons, and the Microbiology Commons Repository Citation Ghosh S. (2017). Different Journeys, Same Destination: Exploring the Role of a PYHIN Protein and Involvement of Caspase-8 in the Regulation and Activation of Inflammasomes. GSBS Dissertations and Theses. https://doi.org/10.13028/M2CD6Z. Retrieved from https://escholarship.umassmed.edu/ gsbs_diss/928 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Different Journeys, Same Destination: Exploring the Role of a PYHIN Protein and Involvement of Caspase-8 in the Regulation and Activation of Inflammasomes A Dissertation Presented By Sreya Ghosh Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY September 12, 2017 Immunology and Microbiology Program Different Journeys, Same Destination: Exploring the Role of a PYHIN Protein and Involvement of Caspase-8 in the Regulation and Activation of Inflammasomes A Dissertation Presented By Sreya Ghosh The signatures of the Dissertation Defense Committee signify Completion and approval as to style and content of the Dissertation ____________________________________________ Katherine A.
    [Show full text]
  • An Integrated Hypothesis for Mir-126 in Vascular Disease Authors Bo Yu1, Yinghua Jiang2, Xiaoying Wang2, Shusheng Wang1,3*
    Shusheng Wang et al. Medical Research Archives vol 8 issue 5. Medical Research Archives REVIEW ARTICLE An integrated hypothesis for miR-126 in vascular disease Authors Bo Yu1, Yinghua Jiang2, Xiaoying Wang2, Shusheng Wang1,3* Affiliations 1Department of Cell and Molecular Biology, Tulane University, 2000 Percival Stern Hall, 6400 Freret Street, New Orleans, LA, 70118, USA 2Department of Neurosurgery 3Department of Ophthalmology, Tulane University School of Medicine, 1430 Tulane Avenue, SL-69, New Orleans, LA 70112, USA Correspondence Shusheng Wang Email: [email protected] Abstract microRNA miR-126 was among the early discovered miRNAs that are expressed specifically in the vasculature and have critical functions in vascular development. Recent studies have started to unveil potentially important function of miR-126 in vascular diseases, including atherosclerosis, coronary artery disease, stroke and diabetic vasculopathy. The action of miR-126 reflects its function in angiogenesis and inflammation. The expression of miR-126 is downregulated in a variety of vascular diseases, and miR-126 overexpression appears to beneficial for most vascular disease models. In the minireview, we summarize the historic and current research regarding miR-126 function and mechanisms in the vascular system, its link to long noncoding RNAs (lncRNA), as well as the potential of miR-126-based therapeutics for vascular diseases. To explain the seemingly conflicting function of miR-126 from different studies, an integrated hypothesis is proposed that miR-126 has strand- and cell type-specific functions in angiogenesis and inflammation, making it beneficial in many different vascular disease models. Copyright 2020 KEI Journals. All Rights Reserved Shusheng Wang et al.
    [Show full text]